EP1196191A4 - Recepteur 5 contenant le domaine de l'apoptose - Google Patents

Recepteur 5 contenant le domaine de l'apoptose

Info

Publication number
EP1196191A4
EP1196191A4 EP00930329A EP00930329A EP1196191A4 EP 1196191 A4 EP1196191 A4 EP 1196191A4 EP 00930329 A EP00930329 A EP 00930329A EP 00930329 A EP00930329 A EP 00930329A EP 1196191 A4 EP1196191 A4 EP 1196191A4
Authority
EP
European Patent Office
Prior art keywords
apoptosis
receptor
field
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00930329A
Other languages
German (de)
English (en)
Other versions
EP1196191A1 (fr
Inventor
Jian Ni
Reiner L Gentz
Guo-Liang Yu
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1196191A1 publication Critical patent/EP1196191A1/fr
Publication of EP1196191A4 publication Critical patent/EP1196191A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00930329A 1999-05-04 2000-05-04 Recepteur 5 contenant le domaine de l'apoptose Withdrawn EP1196191A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13249899P 1999-05-04 1999-05-04
US132498P 1999-05-04
US13323899P 1999-05-07 1999-05-07
US133238P 1999-05-07
US14893999P 1999-08-13 1999-08-13
US148939P 1999-08-13
PCT/US2000/012041 WO2000066156A1 (fr) 1999-05-04 2000-05-04 Recepteur 5 contenant le domaine de l'apoptose

Publications (2)

Publication Number Publication Date
EP1196191A1 EP1196191A1 (fr) 2002-04-17
EP1196191A4 true EP1196191A4 (fr) 2004-03-24

Family

ID=27384298

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00930329A Withdrawn EP1196191A4 (fr) 1999-05-04 2000-05-04 Recepteur 5 contenant le domaine de l'apoptose

Country Status (5)

Country Link
EP (1) EP1196191A4 (fr)
JP (1) JP2002543151A (fr)
AU (1) AU4817200A (fr)
CA (1) CA2369371A1 (fr)
WO (1) WO2000066156A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
AU2002256895B2 (en) * 2001-05-18 2008-09-18 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
EP1439225A4 (fr) 2001-10-04 2005-10-26 Kansai Tech Licensing Org Co Promoteur du gene dr5 et promoteur du gene siah-1
DK1606318T3 (da) * 2003-03-26 2009-11-02 Apogenix Gmbh Forbedrede Fc-fusionsproteiner
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2005114187A2 (fr) * 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Procédés et compositions de diagnostic du sida et d’autres maladies et conditions impliquant l’activation du système immunitaire
WO2006083937A2 (fr) 2005-02-02 2006-08-10 The Uab Research Foundation Agents et methodes associes a la reduction de la resistance aux agonistes des recepteurs de mort induisant l'apoptose
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2011057099A2 (fr) 2009-11-05 2011-05-12 The Uab Research Foundation Traitement de cancers à génotype de type basal
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
MX350202B (es) * 2012-03-28 2017-08-30 Amgen Inc Combinaciones de agonistas de receptores de muerte 5 (dr5).
PT2970473T (pt) 2013-03-14 2017-10-26 Bristol Myers Squibb Co Combinação de agonista de dr5 e antagonista anti-pd-1 e métodos de utilização

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041629A2 (fr) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Recepteur 5 contenant un domaine de mort
EP0870827A2 (fr) * 1997-03-14 1998-10-14 Smithkline Beecham Corporation Récepteur apparenté au facteur de necrose tumorale, TR6
EP1181319A1 (fr) * 1999-05-28 2002-02-27 Genentech, Inc. Anticorps dr4 et utilisation de ces derniers
EP1192185A2 (fr) * 1999-06-09 2002-04-03 Genentech, Inc. Synergie d'agoniste des recepteurs de ligand apo-2 (apo-2l) et de cpt-11
EP1287035A1 (fr) * 2000-05-02 2003-03-05 UAB Research Foundation Un anticorps selectif pour un recepteur de ligand induisant l'apoptose en relation avec le facteur de necrose tumorale et ses utilisations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0870827A2 (fr) * 1997-03-14 1998-10-14 Smithkline Beecham Corporation Récepteur apparenté au facteur de necrose tumorale, TR6
WO1998041629A2 (fr) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Recepteur 5 contenant un domaine de mort
EP1181319A1 (fr) * 1999-05-28 2002-02-27 Genentech, Inc. Anticorps dr4 et utilisation de ces derniers
EP1192185A2 (fr) * 1999-06-09 2002-04-03 Genentech, Inc. Synergie d'agoniste des recepteurs de ligand apo-2 (apo-2l) et de cpt-11
EP1287035A1 (fr) * 2000-05-02 2003-03-05 UAB Research Foundation Un anticorps selectif pour un recepteur de ligand induisant l'apoptose en relation avec le facteur de necrose tumorale et ses utilisations

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CLERICI MARIO ET AL: "Type 1 and type 2 cytokines in HIV infection - A possible role in apoptosis and disease progression", ANNALS OF MEDICINE, vol. 29, no. 3, 1997, pages 185 - 188, XP009024281, ISSN: 0785-3890 *
FRANKFURT OSKAR S ET AL: "Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients", LEUKEMIA RESEARCH, vol. 21, no. 1, 1997, pages 9 - 16, XP001157166, ISSN: 0145-2126 *
GOOCH JENNIFER L ET AL: "Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells", CANCER RESEARCH, vol. 58, no. 18, 15 September 1998 (1998-09-15), pages 4199 - 4205, XP001157169, ISSN: 0008-5472 *
HILL MARK E ET AL: "Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British national lymphoma investigation study", BLOOD, vol. 88, no. 3, 1996, pages 1046 - 1051, XP002267563, ISSN: 0006-4971 *
HORIGOME ATSUSHI ET AL: "Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells", IMMUNOPHARMACOLOGY, vol. 39, no. 1, March 1998 (1998-03-01), pages 21 - 30, XP002267562, ISSN: 0162-3109 *
LINDNER HEIDRUN ET AL: "Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: Role of cytokines", BLOOD, vol. 89, no. 6, 1997, pages 1931 - 1938, XP002267561, ISSN: 0006-4971 *
LOTEM J ET AL: "Interferon-gamma inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells", LEUKEMIA (BASINGSTOKE), vol. 9, no. 4, 1995, pages 685 - 692, XP009024280, ISSN: 0887-6924 *
LOTEM JOSEPH ET AL: "Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor-beta-1 and cancer chemotherapy compounds in myeloid leukemic cells", BLOOD, vol. 80, no. 7, 1992, pages 1750 - 1757, XP001157168, ISSN: 0006-4971 *
ODAKA C ET AL: "Immunosuppressant deoxyspergualin induces apoptotic cell death in dividing cells", IMMUNOLOGY, vol. 95, no. 3, November 1998 (1998-11-01), pages 370 - 376, XP009024297, ISSN: 0019-2805 *
See also references of WO0066156A1 *
SIMONITSCH I ET AL: "Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor alpha (TNF-alpha)", BRITISH JOURNAL OF CANCER, vol. 78, no. 7, October 1998 (1998-10-01), pages 862 - 870, XP009024301, ISSN: 0007-0920 *
ZOU WEIPING ET AL: "Administration of interleukin 13 to simian immunodeficiency virus-infected macaques: Induction of intestinal epithelial atrophy", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 14, no. 9, 10 June 1998 (1998-06-10), pages 775 - 783, XP009024312, ISSN: 0889-2229 *

Also Published As

Publication number Publication date
JP2002543151A (ja) 2002-12-17
AU4817200A (en) 2000-11-17
EP1196191A1 (fr) 2002-04-17
WO2000066156A1 (fr) 2000-11-09
WO2000066156A8 (fr) 2001-07-26
CA2369371A1 (fr) 2000-11-09

Similar Documents

Publication Publication Date Title
CY2014003I1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
EP1171122A4 (fr) Pyrrolidines modulateurs de l'activite du recepteur de chimiokine
PT1235558E (pt) Agentes terapeuticos
DK1176964T3 (da) Brug af ET743 til behandling af cancer
NO20013665L (no) Kaliumsalt av (S)-omeprazol
EP1167388A4 (fr) Fv monocatenaire induisant l'apoptose
MA26818A1 (fr) Formulations contenant des inhibiteurs de lipase
PL354028A1 (pl) Farmaceutyczne roztwory levosimendanuFarmaceutyczne roztwory levosimendanu
DE60036093D1 (de) Antagonisten des gardos-kanals
NO20014926D0 (no) Farmasöytiske forbindelser
PT1022396E (pt) Combinacao de duche
EP1448193A4 (fr) Composes therapeutiques pour le traitement d'etats dyslipidemiques
NO20012106D0 (no) Middel for behandling av benpatobolisme
ATE246502T1 (de) Arzneiformen enthaltend carvedilol
IS6172A (is) Notkun melatoníns til lækninga
FR2808687B1 (fr) Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
EP1572129A4 (fr) Derives d'amidine pour le traitement des amyloses
DE69931264D1 (de) Auslaufgeschütztes trinkbecher
NO20001894L (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
ATE284870T1 (de) Antagonisten des vitronectin-receptors
NO20003799D0 (no) Innkorporering av kolesterol-senkende midler i konfektdosisformer
NO20012226D0 (no) Terapeutiske midler for medikamentavhengighet
NO20016301D0 (no) Terapeutiske midler
ID30381A (id) Penggunaan arilalkanoilpiridazina
FR2791245B3 (fr) Baignoire pour bebes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 01N 37/18 B

Ipc: 7C 07K 14/715 B

Ipc: 7A 61K 45/00 B

Ipc: 7A 61K 38/17 B

Ipc: 7C 07K 16/28 B

Ipc: 7A 61K 39/00 A

Ipc: 7C 07K 14/525 B

Ipc: 7C 07K 14/52 B

Ipc: 7A 61K 39/395 B

A4 Supplementary search report drawn up and despatched

Effective date: 20040206

17Q First examination report despatched

Effective date: 20050811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20071217